First and only PARP inhibitor to improve overall survival in early breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Aims to become India’s leading cancer testing company
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
For people with relapsed or refractory diffuse large B-cell lymphoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Subscribe To Our Newsletter & Stay Updated
